Your browser doesn't support javascript.
loading
Novel mesothelin-targeted chimeric antigen receptor-modified UNKT cells are highly effective in inhibiting tumor progression.
Jiang, Wei; Gu, Guosheng; Zhang, Yumin; Song, Yushuai; Shi, Ming; Wang, Gang; Li, Huizhong; Tao, Tingting; Qin, Jianhua; Li, Xianliang; Jia, Hongtao; Jiao, Feng; Xu, Weidong; Huang, Xiaoyi.
Afiliación
  • Jiang W; Biotherapy Center, Harbin Medical University Cancer Hospital, Harbin 150081, China.
  • Gu G; Abelow Pharmaceuticals Inc., 10 Xinghuo Road, Jiangbei New Area, Nanjing, Jiangsu 210000, China.
  • Zhang Y; Biotherapy Center, Harbin Medical University Cancer Hospital, Harbin 150081, China.
  • Song Y; Biotherapy Center, Harbin Medical University Cancer Hospital, Harbin 150081, China.
  • Shi M; Cancer Institute, Xuzhou Medical University, 209 Tongshan Road, Xuzhou, Jiangsu 221004, China; Jiangsu Center for the Collaboration and Innovation of Cancer Biotherapy, Xuzhou Medical University, 209 Tongshan Road, Xuzhou, Jiangsu 221004, China.
  • Wang G; Cancer Institute, Xuzhou Medical University, 209 Tongshan Road, Xuzhou, Jiangsu 221004, China; Jiangsu Center for the Collaboration and Innovation of Cancer Biotherapy, Xuzhou Medical University, 209 Tongshan Road, Xuzhou, Jiangsu 221004, China.
  • Li H; Cancer Institute, Xuzhou Medical University, 209 Tongshan Road, Xuzhou, Jiangsu 221004, China; Jiangsu Center for the Collaboration and Innovation of Cancer Biotherapy, Xuzhou Medical University, 209 Tongshan Road, Xuzhou, Jiangsu 221004, China.
  • Tao T; CAS Key Laboratory of SSAC, Dalian Institute of Chemical Physics, Chinese Academy of Sciences, Dalian 116023, China.
  • Qin J; CAS Key Laboratory of SSAC, Dalian Institute of Chemical Physics, Chinese Academy of Sciences, Dalian 116023, China; Beijing Institute For Stem Cell and Regenerative Medicine, Chinese Academy of Sciences, Beijing 100020, China; Suzhou Institute for Advanced Research, University of Science and Techno
  • Li X; Department of HBP Surgery，Beijing Chao Yang Hospital，The Capital Medical University, Beijing 100020, China.
  • Jia H; Abelow Pharmaceuticals Inc., 10 Xinghuo Road, Jiangbei New Area, Nanjing, Jiangsu 210000, China.
  • Jiao F; Abelow Pharmaceuticals Inc., 10 Xinghuo Road, Jiangbei New Area, Nanjing, Jiangsu 210000, China.
  • Xu W; Abelow Pharmaceuticals Inc., 10 Xinghuo Road, Jiangbei New Area, Nanjing, Jiangsu 210000, China. Electronic address: xuwd@abelowpharma.com.
  • Huang X; Biotherapy Center, Harbin Medical University Cancer Hospital, Harbin 150081, China; NHC Key Laboratory of Cell Transplantation, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang Province 150001, China. Electronic address: xyhuang@hrbmu.edu.cn.
Pharmacol Res ; 197: 106942, 2023 Nov.
Article en En | MEDLINE | ID: mdl-37775021
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias Ováricas / Neoplasias Hematológicas / Receptores Quiméricos de Antígenos Límite: Animals / Female / Humans Idioma: En Revista: Pharmacol Res Asunto de la revista: FARMACOLOGIA Año: 2023 Tipo del documento: Article País de afiliación: China
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias Ováricas / Neoplasias Hematológicas / Receptores Quiméricos de Antígenos Límite: Animals / Female / Humans Idioma: En Revista: Pharmacol Res Asunto de la revista: FARMACOLOGIA Año: 2023 Tipo del documento: Article País de afiliación: China